Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.
Pascuale CA, Varese A, Ojeda DS, Pasinovich ME, Lopez L, Rossi AH, Rodriguez PE, Miglietta EA; Laboratorio SeVa Group; Mazzitelli I, Di Diego Garcia F, Sanchez L, Rouco SO, Gonzalez Lopez Ledesma MM, Zurano JP, Mazzitelli B, Scruzzi G, Barbero P, Cardozo D, Gallego S, Borda M, Diaz M; Ministerio de Salud de la Provincia de Córdoba Group; UNC-Fac. Cs. Médicas-InViV Group; Ridao F, Rosales AB; Ministerio de Salud de la Provincia de La Rioja Group; Bhon J, Talia JM, Diangelo ME, Lacaze MA; Ministerio de Salud de la Provincia de San Luis Group; Aime B, Gutierrez SI, Ercole R, Toro R, Tau L, Delaplace L, Compagnucci MF; Universidad Nacional de La Plata Group; Sartori C, Desimone I, Echegoyen C, Velazquez P, Testa C; Ministerio de Salud de la Provincia de Buenos Aires Group; Hozbor D, Docena G, Laino CH, Kreplak N, Pifano M, Barbas G, Rearte A, Vizzotti C, Castelli JM, Geffner J, Gamarnik AV.
Pascuale CA, et al. Among authors: rearte a.
Cell Rep Med. 2022 Aug 16;3(8):100706. doi: 10.1016/j.xcrm.2022.100706. Epub 2022 Aug 3.
Cell Rep Med. 2022.
PMID: 35926505
Free PMC article.